Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Princess Margaret Hospital, Ontario, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:3City/State/Province:Ontario
Treatments:ChemotherapyHospital:Princess Margaret Hospital
Drugs:Journal:Link
Date:Sep 2005

Description:

Patients: This Phase II study involved 40 men with hormone resistent prostate cancer. 21 patients had prior radiation therapy and 26 had prior hormone therapy. Metastatic sites included bone, liver, lung, and lymph nodes.

Treatment: The treatment consisted of a chemotherapy drug Gefitinib (Iressa).

Toxicity: Grade 1-3 toxicities included fatigie. Grade 1-2 toxicities included: anorexia, diarrhea, nausea, stomatitis, taste disturbance, and rash.

Results: None of the patients demonstrated a PSA or objective measurable response. The median overall survival was not reported.

Support: The study was supported by AstraZeneca Pharmaceuticals and the NCI of Canada. AstraZeneca manufactures and/or markets Gefitinib.

Correspondence: Malcolm J. Moore, MD





Back